文献速递白血病

Midostaurin降低FLT3突变急性髓系白血病复发:Alliance CALGB 10603/RATIFY试验

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
PubMed 文献 · Leukemia · 2021-03-02

CALGB 10603/RATIFY随机安慰剂对照试验显示,在717例FLT3突变AML患者中,标准一线化疗联合Midostaurin可显著改善总生存,死亡风险降低22%。事后分析表明,Midostaurin组累积复发率(CIR)改善(HR=0.71,95%CI 0.54-0.93,P=0.01),但将移植作为竞争风险后复发风险无显著差异;维持治疗阶段的影响无法确定。

要点

  • Midostaurin联合标准一线化疗可降低FLT3突变AML患者的累积复发率。
  • 将移植作为竞争风险分析时,两臂复发风险无显著差异。
  • 维持治疗阶段对总体结局的影响无法得出结论。

核心结论

  • Midostaurin可降低FLT3突变AML患者的累积复发率。
  • 将移植作为竞争风险后,两臂复发风险无显著差异。
  • 维持治疗阶段对总体结局的影响无法得出结论。

研究设计与样本

  • 前瞻性随机安慰剂对照试验CALGB 10603/RATIFY(Alliance),纳入717例FLT3突变AML患者。
  • 事后分析累积复发率(CIR),并将12个4周周期维持治疗的影响纳入评估。

主要发现

  • Midostaurin组死亡风险降低22%。
  • Midostaurin组CIR改善:HR=0.71(95%CI 0.54-0.93),P=0.01。
  • 在ELN 2017风险分类亚组中,将移植后事件视为事件时CIR亦改善。
  • 将移植作为竞争风险时,两臂复发风险总体无显著差异。

关键数值与推荐

  • CIR分析将复发和AML死亡视为事件,其他原因死亡为竞争风险,缓解期存活者删失。
  • CIR改善:HR=0.71(95%CI 0.54-0.93),P=0.01。
  • 死亡风险降低22%。

临床怎么用

  • 对于FLT3突变AML患者,标准一线化疗联合Midostaurin可考虑用于降低复发风险。
  • 移植作为竞争风险时复发风险差异不显著,需结合移植状态解读CIR结果。
  • 维持治疗阶段对总体结局的影响尚不明确,不能据此推荐。

局限性

  • CIR分析为事后分析。
  • 维持治疗阶段的影响分析无法得出结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostaurin to standard frontline chemotherapy in a genotypically-defined subgroup of 717 patients with FLT3-mutant acute myeloid leukemia (AML). The risk of death was reduced by 22% on the midostaurin-containing arm. In this post hoc analysis, we analyzed the cumulative incidence of relapse (CIR) on this study and also evaluated the impact of 12 4-week cycles of maintenance therapy. CIR analyses treated relapses and AML deaths as events, deaths from other causes as competing risks, and survivors in remission were censored. CIR was improved on the midostaurin arm (HR = 0.71 (95% CI, 0.54-0.93); p = 0.01), both overall and within European LeukemiaNet 2017 risk classification subsets when post-transplant events were considered in the analysis as events. However, when transplantation was considered as a competing risk, there was overall no significant difference between the risks of relapse on the two randomized arms. Patients still in remission after consolidation with high-dose cytarabine entered the maintenance phase, continuing with either midostaurin or placebo. Analyses were inconclusive in quantifying the impact of the maintenance phase on the overall outcome. In summary, midostaurin reduces the CIR.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Larson RA, Mandrekar SJ, Huebner LJ, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021. PMID: 33654204. doi:10.1038/s41375-021-01179-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。